Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

0.57USD
1:30am IST
Change (% chg)

$0.05 (+9.62%)
Prev Close
$0.52
Open
$0.50
Day's High
$0.59
Day's Low
$0.48
Volume
338,376
Avg. Vol
117,634
52-wk High
$3.28
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Announces Commercial Partnership With Emerge Health For Symjepi In Australia And New Zealand
Tuesday, 1 Oct 2019 

Oct 1 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES COMMERCIAL PARTNERSHIP WITH EMERGE HEALTH FOR SYMJEPI® IN AUSTRALIA AND NEW ZEALAND.ADAMIS PHARMACEUTICALS CORP - ADAMIS WILL PROVIDE TECHNICAL SUPPORT TO EMERGE DURING REGISTRATION PROCESS.ADAMIS PHARMACEUTICALS CORP - IF SUCCESSFUL, ADAMIS WILL BEGIN SUPPLYING PRODUCT TO EMERGE.ADAMIS PHARMACEUTICALS - EMERGE WILL BE RESPONSIBLE FOR FULL DISTRIBUTION OF SYMJEPI IN AUSTRALIA AND NEW ZEALAND.ADAMIS PHARMACEUTICALS CORP - ADAMIS AND EMERGE WILL EQUALLY SHARE NET PROFITS.ADAMIS PHARMACEUTICALS CORP - EMERGE DOES NOT ANTICIPATE THAT A COMMERCIAL LAUNCH COULD OCCUR BEFORE 2021..  Full Article

Adamis Pharma Corp - Co Strengthens Patent Portfolio For Its U.S. Compounding Subsidiary
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS CORP - CO STRENGTHENS PATENT PORTFOLIO FOR ITS U.S. COMPOUNDING SUBSIDIARY.  Full Article

Adamis Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Warrants
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.ADAMIS PHARMACEUTICALS CORP - PRICING OF PUBLIC OFFERING OF 12 MILLION SHARES & WARRANTS TO PURCHASE UP TO 12 MILLION SHARES FOR COMBINED PRICE OF $1.00.  Full Article

Adamis Pharmaceuticals Provides Update On Litigation With Belcher Pharmaceuticals
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON LITIGATION WITH BELCHER PHARMACEUTICALS.ADAMIS PHARMACEUTICALS CORP - ADAMIS AND BELCHER PHARMACEUTICALS AGREED TO SETTLE ALL PREVIOUSLY FILED LITIGATION BETWEEN PARTIES.ADAMIS PHARMACEUTICALS CORP - ADAMIS AGREED TO VOLUNTARILY WITHDRAW BOTH PATENT CASE AND IPR.ADAMIS PHARMACEUTICALS - BELCHER AGREED TO PROVIDE CO A WORLDWIDE, NON-EXCLUSIVE, FULLY PAID-UP, ROYALTY-FREE LICENSE RELATING TO PATENTS FOR SYMJEPI.ADAMIS PHARMACEUTICALS CORP - BELCHER AGREED TO NOT TO MAKE FUTURE CLAIMS OF INFRINGEMENT RELATING TO ADAMIS' ZIMHI.  Full Article

Adamis Pharmaceuticals And kaléo Agree To Settle All Previously Announced Litigation Between The Parties
Thursday, 18 Jul 2019 

July 18 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON LITIGATION WITH KALÉO INC..ADAMIS PHARMACEUTICALS CORP - ADAMIS AND KALÉO INC. AGREED TO SETTLE ALL PREVIOUSLY ANNOUNCED LITIGATION BETWEEN PARTIES.ADAMIS PHARMA- KALÉO AGREED NOT TO BRING FUTURE ACTION AGAINST CO ON ZIMHI SO LONG AS CO DOES NOT REFERENCE KALÉO'S PRODUCT IN FUTURE FILING WITH FDA.ADAMIS PHARMACEUTICALS - ADAMIS AGREED NOT TO BRING FUTURE ACTION AGAINST KALÉO FOR ACTS THAT OCCURRED PRIOR TO SETTLEMENT DATE.  Full Article

Adamis Pharmaceuticals Provides Update On Its Higher Dose Naloxone Injection Product
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS - FDA HAS ACKNOWLEDGED RECEIPT OF CO'S AMENDMENT TO PREVIOUSLY SUBMITTED NDA FOR ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS - REVISION REMOVED EVZIO AS A REFERENCE LISTED DRUG AND WITHDREW ASSOCIATED PARAGRAPH IV CERTIFICATION.ADAMIS PHARMACEUTICALS - BELIEVES AMENDED NDA WILL NOT BE SUBJECT TO A 30-MONTH STAY.ADAMIS PHARMACEUTICALS - BELIEVES FDA WILL BE FREE TO ISSUE APPROVAL AS SOON AS IT COMPLETES A SATISFACTORY REVIEW OF CO'S NALOXONE NDA.ADAMIS PHARMACEUTICALS CORP - DECIDED TO AMEND ITS ORIGINAL NDA AFTER CONSULTING WITH FDA REGARDING PROPOSED CHANGE.ADAMIS PHARMACEUTICALS - REMOVAL OF PARAGRAPH IV CERTIFICATION DOES NOT TERMINATE PREVIOUSLY ANNOUNCED LAWSUIT FILED BY KALÉO INC.  Full Article

Adamis Pharmaceuticals Q1 Revenue $4.9 Million
Friday, 10 May 2019 

May 9 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q1 REVENUE $4.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $5.8 MILLION.CASH AND EQUIVALENTS AT END OF Q1 WAS $9.2 MILLION.  Full Article

Adamis Pharmaceuticals Announces 2018 Financial Results And Provides Business Update
Saturday, 16 Mar 2019 

March 15 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AT DEC 31 2018, CO HAD CASH AND CASH EQUIVALENTS OF $19.3 MILLION.  Full Article

Adamis Pharmaceuticals Announces FDA Acceptance For Review Of The New Drug Application Of Its Higher Dose Naloxone Injection Product Candidate
Friday, 15 Mar 2019 

March 14 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF THE NEW DRUG APPLICATION OF ITS HIGHER DOSE NALOXONE INJECTION PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER PROVIDED A TARGET AGENCY ACTION DATE OF OCTOBER 31, 2019.ADAMIS PHARMACEUTICALS CORP -FDA HAD DETERMINED THAT NDA WAS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW.  Full Article

Adamis Provides Regulatory Update On Sublingual Tadalafil
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.FDA REQUESTED CO SUPPLEMENT AND INCLUDE IN RESUBMITTED NDA LONGER REAL-TIME (VERSUS ACCELERATED) STABILITY DATA.ADAMIS PROVIDES REGULATORY UPDATE ON SUBLINGUAL TADALAFIL.ADAMIS PHARMACEUTICALS - RECEIVED A REFUSAL TO FILE LETTER FROM FDA REGARDING ITS NEW DRUG APPLICATION (NDA) FOR ITS SUBLINGUAL TADALAFIL PRODUCT.FDA DETERMINED THAT SUBMITTED NDA WAS NOT SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW.ADAMIS PHARMACEUTICALS- RECEIVED REFUSAL TO FILE LETTER FROM UNITED STATES FDA REGARDING NEW DRUG APPLICATION NDA FOR ITS SUBLINGUAL TADALAFIL PRODUCT.ADAMIS PHARMACEUTICALS - FDA REQUESTED CO SUPPLEMENT & INCLUDE IN RESUBMITTED NDA ADDITIONAL DISSOLUTION DATA FOR BOTH CLINICAL & REGISTRATION BATCHES.MAY SEEK IMMEDIATE GUIDANCE FROM FDA, INCLUDING REQUESTING A TYPE A MEETING, TO DISCUSS LETTER.  Full Article

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

July 9 A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.